SPECIAL NOTICE
A -- Intent to Sole Source: Dihexa Prep and Supply & Molecular Analysis Services
- Notice Date
- 7/14/2020 7:39:47 AM
- Notice Type
- Special Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- W4PZ USA MED RSCH ACQUIS ACT FORT DETRICK MD 21702-5014 USA
- ZIP Code
- 21702-5014
- Solicitation Number
- 20-9-0000-004996SS
- Response Due
- 7/20/2020 7:00:00 AM
- Archive Date
- 08/04/2020
- Point of Contact
- Kathleen Hamilton, Phone: 3016191078
- E-Mail Address
-
kathleen.e.hamilton4.mil@mail.mil
(kathleen.e.hamilton4.mil@mail.mil)
- Description
- This is a Research and Development Notice of Intent to Sole Source, NOT a Request for Proposal. This is a Notice of Intent to Sole Source Only and shall not be construed as a solicitation or as an obligation on the part of Madigan Army Medical Center (MAMC)�or the US Army Medical Research Acquisition Activity (USAMRAA). This is a special notice of intent to sole source to an organization that has the knowledge and capabilities to perform Dihexa Preparation and Supply, and Molecular Analysis Services on behalf of MAMC.� The objective of the proposed study Dihexa would enhance peripheral nerve regeneration and muscles innervation.�� Scope / Key Tasks: �-�Procure, prepare and provide Dihexa and/or other relevant drugs, and assist in prepare hydrogel with Dihexa, as needed for the project. -�Perform control experiments (Dihexa or G-CSF-untreated), using tissues obtained from normal animals, and study baseline for Dihexa target (HCF/c-Met) engagement and downstream targets including STAT3, STAT5, JAK2, ERK and AKT. -�Study activated growth factor (HGF) receptor, total receptor expression and activated downstream targets in the skeletal muscle samples taken from distal (graft) and proximal (native) to limb transplant site, and spinal cord/nerve tissue samples. -�Analyze relevant signaling molecules/transcription factors to study mechanistic action of Dihexa or G-CSF, and establish baseline levels in animals that do not receive Dihexa or G-CSF. -�Conduct Dihexa and G-CSF target validation: perform immunoblot and immunochemistry analysis for Dihexa target (HGF/c-Met). -�Study cell signaling mechanisms and/or transcription factors involved in the tissues of interest following Dihexa or G-CSF therapy. -Assists in the preparation of abstracts and manuscripts for presentations/publications, and progress reports for funding agency. The estimated period of performance would be TBD September 2020 � TBD September, 2023 (Base and Two (2) � 1 Year Option periods). No reimbursement will be made of any costs to provide information in response to this announcement or any follow up information requests.� Availability of any formal solicitation will be announced under a separate announcement.� THIS NOTICE OF INTENT IS NOT A REQUEST FOR COMPETITIVE QUOTATIONS. Responsible, interested parties may identify their interest by submitting capability information, by deadline specified to Major Kate Hamilton at kathleen.e.hamilton4.mil@mail.mil.� Supporting evidence must be furnished in sufficient detail to demonstrate the firm�s ability to provide the stated capability. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, USAMRAA will proceed with the sole source contract.
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/350d6a254a1a4f7cb068e941149d16b6/view)
- Place of Performance
- Address: Joint Base Lewis McChord, WA 98431, USA
- Zip Code: 98431
- Country: USA
- Zip Code: 98431
- Record
- SN05720005-F 20200716/200714230154 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |